XML 41 R30.htm IDEA: XBRL DOCUMENT v3.25.2
Collaboration and License Agreements - Additional Information (Details) - Collaborative Arrangement
$ / shares in Units, $ in Millions
 3 Months Ended 6 Months Ended 12 Months Ended
Jun. 30, 2025
USD ($)
Mar. 31, 2025
USD ($)
Jun. 30, 2024
USD ($)
Mar. 31, 2024
USD ($)
Mar. 31, 2023
$ / shares
shares
Jun. 30, 2025
USD ($)
preclinicalCandidate
undisclosedProgram
geneTherapyProgram
non-clinicalStageCompound
Dec. 31, 2022
$ / shares
shares
Dec. 31, 2021
$ / shares
shares
Dec. 31, 2019
$ / shares
shares
Common Stock | Voyager                  
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                  
Beneficial ownership (as a percent)         19.90%        
Nxera                  
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                  
Research and development $ 15.0   $ 15.0            
Potential milestone payments 2,500.0         $ 2,500.0      
Agreement termination, minimal contractual time (in days)           180 days      
Agreement termination, contractual time threshold (in days)           90 days      
Agreement termination by counterparty, contractual time threshold (in days)           365 days      
Agreement termination by counterparty, minimal contractual time (in days)           120 days      
Takeda                  
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                  
Research and development   $ 37.5 7.5            
Potential milestone payments 700.0         $ 700.0      
Agreement termination, minimal contractual time (in days)           6 months      
Agreement termination, contractual time threshold (in days)           12 months      
Number of non-clinical stage compounds | non-clinicalStageCompound           3      
Xenon                  
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                  
Research and development 7.5                
Potential milestone payments 1,700.0         $ 1,700.0      
Agreement termination, contractual time threshold (in days)           90 days      
Number of preclinical candidates | preclinicalCandidate           3      
Sale of stock (in shares) | shares             300,000 300,000 1,400,000
Share price (in USD per share) | $ / shares             $ 31.855 $ 19.9755 $ 14.196
2019 Voyager Agreement                  
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                  
Research and development       $ 5.0          
Potential milestone payments 500.0         $ 500.0      
Agreement termination, minimal contractual time (in days)           180 days      
Agreement termination, contractual time threshold (in days)           1 year      
Share price (in USD per share) | $ / shares                 $ 11.9625
Number of undisclosed programs | undisclosedProgram           2      
2019 Voyager Agreement | Common Stock                  
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                  
Sale of stock (in shares) | shares                 4,200,000
Transfer, beneficial ownership, and voting restrictions period (in years)         3 years        
2023 Voyager Agreement                  
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                  
Research and development     $ 3.0            
Potential milestone payments 6,100.0         $ 6,100.0      
Agreement termination, minimal contractual time (in days)           180 days      
Agreement termination, contractual time threshold (in days)           1 year      
Share price (in USD per share) | $ / shares         $ 8.88        
Number of gene therapy programs | geneTherapyProgram           3      
Board of directors maximum duration term (in years)         10 years        
2023 Voyager Agreement | Common Stock                  
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                  
Sale of stock (in shares) | shares         4,400,000        
Transfer, beneficial ownership, and voting restrictions period (in years)         3 years        
Sanofi S.A                  
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                  
Potential milestone payments $ 10.0         $ 10.0      
Sanofi S.A | Minimum                  
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                  
Royalties at tiered percentage (as a percent) 3.00%         3.00%      
Sanofi S.A | Minimum | Patents                  
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                  
Patent term (in years)           16 years      
Sanofi S.A | Maximum                  
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                  
Royalties at tiered percentage (as a percent) 5.00%         5.00%      
MTPC                  
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                  
Agreement termination, contractual time threshold (in days)           180 days      
Potential milestone payment receipts $ 30.0         $ 30.0      
MTPC | Minimum | Patents                  
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                  
Patent term (in years)           10 years      
AbbVie                  
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                  
Agreement termination, contractual time threshold (in days)           180 days      
Potential milestone payment receipts $ 366.0         $ 366.0      
AbbVie | Minimum | Patents                  
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                  
Patent term (in years)           10 years